TFT

• Antineoplastic Agents
• Photosensitizing Agents
• ATC:L01XD02

• F3DThd
• F3T
• F3TDR
• Fluridine
• TFDU
• TFT
• Trifluoromethyldeoxyuridine
• Trifluorothymidine
• Trifluridina [INN-Spanish]
• Trifluridine [USAN:INN]
• Trifluridinum [INN-Latin]
• Virophta
• Viroptic
• trifluorothymine deoxyriboside

• No information avaliable

C₄₁H₄₂N₄O₈

http://www.rxlist.com/cgi/generic2/verteporfin.htm

TFT FDA

No information avaliable

718.794 g/mol

No information avaliable

No information avaliable

Solid

3.743

Powder for solution to be mixed for injection (2mg verteporfin/mL reconstituted verteporfin)

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

No information avaliable

Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to bright light.

Humans and other mammals